Amarin (AMRN) Higher as Teva (TEVA) Said to be Waiting in the Wings for a Takeover
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/26/2026
- Nasdaq lags on angst over AI spending ahead of earnings reports
- Elon Musk’s trillion-dollar meltdown: How SpaceX and Tesla erased $700 billion
- Intel jumps 10% after AI-fueled quarter crushes estimates, upbeat outlook
- Oil falls on report China pushing for end US-Iran war
- Why Meta, Microsoft, and Nvidia are championing open-weight AI
- FDA approves Tylenol with Naproxen as first OTC combo pain reliever
- AMD (AMD) PT Raised to $1,250 at Baird
- Pakistan, Iran explore path towards new talks with US in a China-initiated push, sources say
- Elon Musk’s trillion-dollar meltdown: How SpaceX and Tesla erased $700 billion
- Nasdaq lags on angst over AI spending ahead of earnings reports
Groundhog Day for Amarin (AMRN); MKM Not Positive on NCE Status Although Company Remains Upbeat
November 19, 2012 10:42 AM ESTAnalysts at MKM Partners commented on Amarin Corporation (NASDAQ: AMRN) after the FDA updated the Orange Book for October and once again failed to rule on NCE status for Vascepa.
MKM's Jon LeCroy notes this is the fourth delay and he assumes that it is unlikely that Amarin will be able to successfully petition the FDA to grant Vascepa NCE status. However,... More
